Homo sapiens
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA285104 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Whole skin treated with Ruxolitinib, tofacitinib or vehicle control for 4 days
| PRJNA285103 | ENA
Project description:Day 0= whole skin from C57/B6 female at 8.5 weeks of age Day5= whole skin from C57/B6 female after 4 days of treatment with vehicle, ruxolitinib or tofacitinib
2018-05-27 | GSE69300 | GEO
Project description:To define the molecular response to JAKi treatment, we performed RNA-seq analysis on a series of skin biopsies taken before and after systemic treatment with INCB039110 (JAK1i), CEP-33779 (JAK2i), PF-06651600 (JAK3i), ruxolitinib (JAK1/2i), tofacitinib (pan-JAKi) or vehicle control.
2021-02-24 | GSE167360 | GEO
Project description:Dermal papilla cells isolated from the human hair follicle are capable of inducing hair growth in recipient epithelia. However, demonstrating disparity from rodent dermal papilla, human cells lose this inductive competance immediately upon growth in culture under normal growth conditions. We grew dermal papilla cells in hanging drop cultures that are morphologically akin to intact dermal papilla, and found that by enhancing the environment for aggregation, we could restore the inductive capacity of human dermal papilla cells in culture. The underlying genes that regulate the inductive potential of dermal papilla cells is not well understood, and we sought to use global profiling to identify key genes and pathways related to inductive competance within dermal papilla cells. We used Affymetrix microarrays to profile human dermal papilla cells in both hair inducing, and non-hair inducing states. Affymetrix microarrays were used to to perform profiling of human dermal papilla cells, both as intact tissues (freshly isolated from scalp), and at several stages in subsequent two dimensional culture; cell explant outgrowths (p0), cells at passage 1 (p1), passage 3 (p3) and passage 5 (p5). RNA was isolated from cultured cells 72 hours after feeding. Cells at passage 3 were also grown in hanging drops to form dermal spheroids, that were used for RNA collection 48 hours after establishment. All experiments were performed using tissue from three biological replicates (#D5, D6, D7),
2013-10-20 | E-GEOD-44765 | biostudies-arrayexpress
Project description:Our goal was to identify gene expression patterns that correlated with treatment of established autoimmune alopecia in C3H/HeJ mice following alopecic graft transplantation skin from 3 mice were taken at 6, 12 and, in some cases, 24 weeks of topical drug administration following grafting; mice were treated with ruxolitinib (jak1i), tofacitinib (jak3i), or control pbs 3 biological replicates were taken at each time point for each treatment modality
2014-08-17 | E-GEOD-45514 | biostudies-arrayexpress
Project description:Our goal was to identify gene expression patterns that correlated with treatment of established autoimmune alopecia in C3H/HeJ mice following alopecic graft transplantation skin from 3 mice were taken at 6, 12 and, in some cases, 24 weeks of topical drug administration following grafting; mice were treated with ruxolitinib (jak1i), tofacitinib (jak3i), or control pbs
2014-08-17 | GSE45514 | GEO
Project description:The myeloma bone marrow microenvironment drives proliferation of malignant plasma cells and promotes resistance to therapy. Interleukin-6 (IL-6) and downstream JAK/STAT signaling are thought to be central components of these microenvironment-induced phenotypes. In a prior drug repurposing screen, we identified tofacitinib, a pan-JAK inhibitor FDA-approved for rheumatoid arthritis, as an agent that may reverse the tumor-stimulating effects of bone marrow mesenchymal stromal cells.Here, we validated both in vitro, in stromal-responsive human myeloma cell lines, and in vivo, in orthotopic disseminated murine xenograft models of myeloma, that tofacitinib showed both single-agent and combination therapeutic efficacy in myeloma models. Surprisingly, we found that ruxolitinib, an FDA-approved agent targeting JAK1 and JAK2, did not lead to the same anti-myeloma effects. Combination with a novel irreversible JAK3-selective inhibitor also did not rescue ruxolitinib effects. RNA-seq and unbiased phosphoproteomics revealed that marrow stromal cells drive a JAK/STAT-mediated proliferative program in myeloma plasma cells, and tofacitinib reversed the large majority of these pro-growth signals. Taken together, our results suggest that tofacitinib specifically reverses the growth-promoting effects of the tumor microenvironment through blocking an IL-6-mediated signaling axis. As tofacitinib is already FDA-approved, these results can be rapidly translated into potential clinical benefits for myeloma patients.
2018-10-24 | PXD006581 | Pride
Project description:Dermal papilla cells isolated from the human hair follicle are capable of inducing hair growth in recipient epithelia. However, demonstrating disparity from rodent dermal papilla, human cells lose this inductive competance immediately upon growth in culture under normal growth conditions. We grew dermal papilla cells in hanging drop cultures that are morphologically akin to intact dermal papilla, and found that by enhancing the environment for aggregation, we could restore the inductive capacity of human dermal papilla cells in culture. The underlying genes that regulate the inductive potential of dermal papilla cells is not well understood, and we sought to use global profiling to identify key genes and pathways related to inductive competance within dermal papilla cells. We used Affymetrix microarrays to profile human dermal papilla cells in both hair inducing, and non-hair inducing states.
2013-10-20 | GSE44765 | GEO
Project description:Cells were treated for thirty minutes with ruxolitinib or DMSO as vehicle control prior to exposure for three hours with 400 ng/ml IL-6 and 200 ng/ml sIL6Ra.
2020-12-22 | GSE163649 | GEO
Project description:Our goal was to identify gene expression patterns that correlated with prevention of autoimmune alopecia in C3H/HeJ mice following alopecic graft transplantation skin from 3-5 mice were taken at 5/6 weeks and 12/13 weeks of drug administration following grafting; mice were treated with ruxolitinib (jak12i) by oral gavage, tofacitinib (jak3i) by osmotic pump, antiIL15R-beta antibody by i.p. injection, or control pbs by either ip injection, oral gavage, or osmotic pump. sham indicates mice that received no graft. 3-5 biological replicates were taken at each time point for each treatment modality
2014-08-17 | E-GEOD-45551 | biostudies-arrayexpress